Table 1.
Baseline patient demographic, clinical, angiographic, and procedural data according to TSH level
| Variables | Normal TSH (n = 1846) | Elevated TSH (n = 131) | P value |
|---|---|---|---|
| Demographics | |||
| Age (year) | 61.4 ± 12.8 | 67.8 ± 11.1 | <0.001 |
| Age ≥ 65 years | 934 (50.6) | 100 (76.3) | <0.001 |
| Female gender | 471 (22.5) | 59 (45.0) | <0.001 |
| Risk factors | |||
| BMI (kg/m2) | 24.3 ± 3.2 | 23.8 ± 3.2 | 0.101 |
| Diabetes mellitus | 628 (34.0) | 45 (34.4) | 0.938 |
| Hypertension | 935 (50.7) | 74 (56.5) | 0.196 |
| Atrial fibrillation | 71 (3.9) | 17 (13.0) | <0.001 |
| Current smoking | 781 (42.3) | 50 (38.2) | 0.354 |
| Family history of CAD | 119 (6.4) | 3 (2.3) | 0.056 |
| Prior history of stroke | 117 (6.3) | 16 (12.2) | 0.009 |
| Prior history of myocardial infarction | 40 (3.8) | 8 (6.1) | 0.188 |
| Prior history of PCI | 60 (3.3) | 7 (5.3) | 0.206 |
| Prior history of CABG | 30 (1.6) | 3 (2.3) | 0.478 |
| Hemodynamic status | |||
| Initial systolic blood pressure (mmHg) | 129.1 ± 30.5 | 126.5 ± 30.4 | 0.350 |
| Initial diastolic blood pressure (mmHg) | 78.4 ± 18.8 | 77.1 ± 19.1 | 0.470 |
| Initial heart rate | 76.6 ± 20.1 | 78.3 ± 21.2 | 0.337 |
| Killip classes II‐IV | 342 (18.5) | 27 (20.6) | 0.558 |
| Primary diagnosis at admission | 0.001 | ||
| STEMI | 1175 (63.7) | 65 (49.6) | |
| NSTEMI | 671 (36.3) | 66 (50.4) | |
| Discharge medication | |||
| Statin | 1708/1802 (94.8) | 113/123 (91.9) | 0.167 |
| Beta‐blocker | 1301/1802 (72.2) | 89/123 (72.4) | 0.977 |
| ACEI/ARB | 1372/1802 (76.1) | 98/123 (79.7) | 0.372 |
| Laboratory data | |||
| LVEF (%) | 53.3 ± 11.0 | 51.6 ± 11.4 | 0.103 |
| LVEF <40% | 191/1781 (10.7) | 20/121 (16.5) | 0.049 |
| FT4 | 1.19 ± 0.20 | 1.08 ± 0.29 | <0.001 |
| TSH | 1.28 ± 0.88 | 11.52 ± 33.42 | 0.001 |
| Glucose (mg/dL) | 170.1 ± 79.2 | 175.2 ± 81.5 | 0.511 |
| Creatinine (mg/dL) | 1.15 ± 0.88 | 1.19 ±0.66 | 0.468 |
| eGFR, mL/min/1.73 m2 | 76.6 ± 26.4 | 68.7 ± 27.8 | 0.001 |
| eGFR <60 mL/min/1.73 m2 | 400 (21.7) | 53 (40.5) | <0.001 |
| Hs‐CRP (mg/L) | 2.20 ± 4.04 | 1.72 ± 2.70 | <0.001 |
| CK‐MB (ng/mL) | 114.8 ± 144.4 | 96.0 ± 142.1 | 0.150 |
| Troponin‐I (ng/mL) | 26.8 ± 42.7 | 21.1 ± 33.2 | 0.563 |
| Total cholesterol (mg/dL) | 180.9 ± 40.3 | 181.1 ± 32.8 | 0.960 |
| Triglycerides (mg/dL) | 123.5 ± 88.6 | 133.5 ± 123.0 | 0.239 |
| HDL cholesterol (mg/dL) | 41.6 ± 10.1 | 41.4 ± 11.6 | 0.848 |
| LDL cholesterol (mg/dL) | 114.8 ± 35.0 | 112.6 ± 37.0 | 0.529 |
| Angiographic and procedural data | |||
| Glycoprotein IIb‐IIIa inhibitor | 93 (5.0) | 8 (6.1) | 0.591 |
| IABP | 47 (2.5) | 3 (2.3) | 1.000 |
| ECMO | 2 (0.1) | 0 (0) | 1.000 |
| Culprit vessel, n (%) | 0.605 | ||
| Left main | 47 (2.5) | 4 (3.1) | |
| Left anterior descending artery | 894 (48.4) | 68 (51.9) | |
| Left circumflex artery | 291 (15.8) | 20 (15.3) | |
| Right coronary artery | 614 (33.3) | 39 (29.8) | |
| Involved vessels, n (%) | 0.114 | ||
| One vessel | 833 (45.1) | 64 (48.9) | |
| Two vessels | 593 (32.1) | 31 (23.7) | |
| Three vessels | 420 (22.8) | 36 (27.5) | |
| Pre‐PCI TIMI flow grade 0, n (%) | 741 (43.2) | 49 (42.2) | 0.839 |
| Post‐PCI TIMI flow grade III, n (%) | 1583 (88.8) | 107 (84.3) | 0.118 |
Abbreviations: ACEI/ARB, angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker; AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CK‐MB, creatine kinase‐MB fraction; ECMO, extracorporeal membrane oxygenator; eGFR, estimated glomerular filtration rate; FT4, free thyroxine; HDL, high‐density lipoprotein; Hs‐CRP, high‐sensitivity C‐reactive protein; IABP, intra‐aortic balloon pulsation; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; NSTEMI, non‐ST‐segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI,ST‐segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction; TSH, thyroid‐stimulating hormone.
Data are presented as the mean ± standard deviation or n (%).